S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:BDSX

Biodesix Stock Forecast, Price & News

$15.44
-0.93 (-5.68 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$15.05
Now: $15.44
$16.99
50-Day Range N/A
52-Week Range
$10.85
Now: $15.44
$19.13
Volume85,838 shs
Average Volume286,875 shs
Market Capitalization$405.36 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests provide physicians with timely results to facilitate treatment decisions. It also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as develops and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated 2005 and is headquartered in Boulder, Colorado.

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.83 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BDSX
CUSIPN/A
CIKN/A
Phone303-417-0500
Employees154

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$405.36 million
Next Earnings DateN/A
OptionableNot Optionable
$15.44
-0.93 (-5.68 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BDSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Biodesix (NASDAQ:BDSX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Biodesix?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biodesix in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Biodesix
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Biodesix?

Wall Street analysts have given Biodesix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biodesix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for BDSX?

4 brokerages have issued 12-month price targets for Biodesix's stock. Their forecasts range from $20.00 to $26.00. On average, they expect Biodesix's stock price to reach $22.67 in the next year. This suggests a possible upside of 46.8% from the stock's current price.
View analysts' price targets for Biodesix
.

Who are some of Biodesix's key competitors?

Who are Biodesix's key executives?

Biodesix's management team includes the following people:
  • Mr. Scott Hutton, Pres, CEO & Director (Age 48, Pay $298.48k)
  • Ms. Robin Harper Cowie, CFO, Sec. & Treasurer (Age 40, Pay $263.52k)
  • Dr. Heinrich Röder, Founder & CTO
  • Mr. Robert E. Cawthorn, Founder & Director Emeritus (Age 85)
  • Mr. Jeffrey A. Bojar, VP of Legal and Regulatory Affairs
  • Mr. Matt Stauffer, VP of Sales
  • Mr. Jim Purvis, VP of HR & Operational Effectiveness
  • Dr. Paul J. Beresford, Chief Bus. Officer
  • Dr. Gary Anthony Pestano, Chief Devel. Officer (Age 53)
  • Dr. Robert W. Georgantas III, Ph.D., Sr. VP of Research & Translational Science (Age 50)

When did Biodesix IPO?

(BDSX) raised $76 million in an initial public offering on Wednesday, October 28th 2020. The company issued 4,200,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is Biodesix's stock symbol?

Biodesix trades on the NASDAQ under the ticker symbol "BDSX."

When does the company's quiet period expire?

Biodesix's quiet period expires on Monday, December 7th. Biodesix had issued 4,000,000 shares in its public offering on October 28th. The total size of the offering was $72,000,000 based on an initial share price of $18.00. During the company's quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Biodesix?

Shares of BDSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biodesix's stock price today?

One share of BDSX stock can currently be purchased for approximately $15.44.

How big of a company is Biodesix?

Biodesix has a market capitalization of $405.36 million. Biodesix employs 154 workers across the globe.

What is Biodesix's official website?

The official website for Biodesix is www.biodesix.com.

How can I contact Biodesix?

The company can be reached via phone at 303-417-0500.

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.